Do GLP-1-Based Therapies Increase Cancer Risk?

Do GLP-1–Based Therapies Increase Cancer Risk?

Cases of pancreatitis have been described in connection with the use of exenatide (1), liraglutide (2) and other glucagon-like peptide (GLP)-1 receptor agonists. From these findings, the following hypothesis has been generated: stimulating the GLP-1 receptor with respective agonists has a potential to cause pancreatitis, perhaps chronic pancreatitis, and in the long term, potentially even pancr...

Do thyroid disorders increase the risk of breast cancer?

The objective of this study was to determine whether thyroid disorders or treatment of such disorders affects the risk of breast cancer. Subjects aged 35-64 years were participants in the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study, a population-based, case-control study of invasive breast cancer that was carried out at five ...

GLP-1–Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus

Pharmacological agents that are based on the gut-derived hormone glucagon-like peptide (GLP)-1 are increasingly used for hyperglycemia management in type 2 diabetes mellitus. Both GLP-1 receptor agonists and inhibitors of the GLP-1–degrading enzyme dipeptidyl peptidase-4 (ie, DPP-4 inhibitors) increase insulin and reduce glucagon secretion, thereby lowering plasma glucose levels. Moreover, GLP-...

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and have the potential to be effective antiobesity agents. Although widely known as an incretin hormone, there is a growing body of evidence that GLP-1 als...

Comparison of efficacy between different incretin-based therapies; GLP-1 agonists and DPP-4 inhibitors